We’ll Continue Hydroxychloroquine Clinical Trials – NAFDAC

NAFDAC DG, Mojisola Adeyeye
NAFDAC DG, Mojisola Adeyeye

The National Agency for Food and Drug Administration and Control (NAFDAC) has announced that it will continue hydroxychloroquine clinical trials for the treatment of COVID-19 in Nigeria.

This is coming despite the suspension of the same trial by the World Health Organisation.

Also Read: Come Forward With Your Drugs, NAFDAC To Those Claiming To Have COVID-19 Cure

NAFDAC Director-General, Prof Mojisola Adeyeye, made this known on Tuesday during a programme on Television Continental.

Adeyeye said there are proven records that hydroxychloroquine had been effective in the treatment of COVID-19 patients, especially those at the “mild stage” of the virus.

LEAVE A REPLY

Please enter your comment!
Please enter your name here